Sugi Predict

Sugi Predict / Compounds / SCHEMBL734928

SCHEMBL734928

SCHEMBL734928

CC(C)(C)OC(=O)CNCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.55
▸ CA12 O43570 1/20 0.52
▸ CA1 P00915 1/20 0.52
▸ CA7 P43166 1/20 0.52
▸ CA14 Q9ULX7 1/20 0.52
▸ PPID Q08752 1/20 0.48
▸ RECQL P46063 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ RIPK1 Q13546 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ PTPRC P08575 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ MITF O75030 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ AKT1 P31749 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6433307 0.98 ATM (0.53) ATMCA12CA1CA7CA14
SCHEMBL7863508 0.88 BCHE (0.60) KMT2A
SCHEMBL1243790 0.86 ALDH1A1 (0.51) ATMSMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL14205020 0.85 KMT2A (0.46) ATMSMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL13662612 0.85 ATM (0.44) ATMCA12CA1CA7CA14
SCHEMBL15876277 0.85 MTNR1A (0.42) ATMCA12CA1CA7CA14
SCHEMBL8421187 0.85 VSIR (0.44) ATMCA1GAA
SCHEMBL5038405 0.84 MEP1B (0.60) CA1SMN1; SMN2
SCHEMBL8139519 0.84 TPSAB1 (0.45) ATMGAA
SCHEMBL9102803 0.84 ATM (0.52) ATMCA12CA1CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025045106-A1 PI3Kα INHIBITOR AND USE THEREOF 郑州同源康医药有限公司 2025-03-06 — — WO disclosed
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2024-01-18 — — US disclosed
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2024-01-18 — — US disclosed
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2024-01-18 — — US disclosed
US-11859018-B2 Peptoid-based chelating ligands for selective metal chelation TRIAD NATIONAL SECURITY, LLC (US) 2024-01-02 — — US disclosed
CN-116670143-A Modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-08-29 — — CN disclosed
EP-4225447-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
US-20230150946-A1 HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS OXFORD FINANCE LLC 2023-05-18 — — US disclosed
WO-2023029943-A1 AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 星药科技(北京)有限公司 2023-03-09 — — WO disclosed
US-20220135623-A1 PEPTOID-BASED CHELATING LIGANDS FOR SELECTIVE METAL CHELATION U.S. DEPARTMENT OF ENERGY 2022-05-05 — — US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 — — WO disclosed
US-5891852-A Serine protease inhibitors-cycloheptane derivatives CORTECH, INC. (US) 1999-04-06 — — US disclosed
US-5869455-A SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE PEPTOIDS WHICH ARE USEFUL AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE CORTECH, INC. (US) 1999-02-09 — — US disclosed
US-5807829-A RESPIRATORY SYSTEM DISORDERS; SESPIC SHOCK; ORGAN FAILURE CORTECH, INC. (US) 1998-09-15 — — US disclosed
US-5801148-A Serine protease inhibitors-proline analogs CORTECH, INC. (US) 1998-09-01 — — US disclosed
US-5573752-A Aromatic amide compounds and metal chelates thereof BRACCO INTERNATIONAL B.V. 1996-11-12 — — US disclosed
EP-0702677-A1 AROMATIC AMIDE COMPOUNDS AND METAL CHELATES THEREOF BRACCO International B.V. (NL) 1996-03-27 — — EP disclosed
WO-1995027705-A1 AROMATIC AMIDE COMPOUNDS AND METAL CHELATES THEREOF BRACCO INTERNATIONAL B.V. (NL) 1995-10-19 — — WO disclosed
US-4069318-A INHIBITION AND SUPPRESSION OF THROMBOSIS MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) 1978-01-17 — — US disclosed
US-4018915-A ANTITHROMBOTIC MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) 1977-04-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150946-A1 HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS STAT5A, STAT5B, STAT3 ATM 322/4885CA12 4517/4885CA1 4329/4885
US-20220135623-A1 PEPTOID-BASED CHELATING LIGANDS FOR SELECTIVE METAL CHELATION SLC39A14, SLC39A11, SLC40A1 ATM 1720/4885CA12 755/4885CA1 597/4885
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B ATM 1874/4885CA12 4587/4885CA1 4871/4885
US-11859018-B2 Peptoid-based chelating ligands for selective metal chelation SLC39A14, SLC39A11, SLC40A1 ATM 1720/4885CA12 755/4885CA1 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.